tradingkey.logo

Veru Reports Positive Safety Results From Phase 2B Quality Study

ReutersMay 28, 2025 11:44 AM

- Veru Inc VERU.O:

  • VERU REPORTS POSITIVE SAFETY RESULTS FROM PHASE 2B QUALITY STUDY: ENOBOSARM ADDED TO SEMAGLUTIDE LED TO GREATER FAT LOSS, PRESERVATION OF MUSCLE, AND FEWER GASTROINTESTINAL SIDE EFFECTS COMPARED TO SEMAGLUTIDE ALONE

  • VERU INC - TOPLINE DATA FOR PHASE 2B EXTENSION STUDY EXPECTED IN SECOND QUARTER

  • VERU INC: TRIAL MET ITS PRESPECIFIED PRIMARY ENDPOINT

  • VERU INC - REQUESTS END OF PHASE 2 MEETING WITH FDA FOR PHASE 3 REGULATORY CLARITY

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI